<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735826</url>
  </required_header>
  <id_info>
    <org_study_id>D-0828</org_study_id>
    <nct_id>NCT00735826</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer</brief_title>
  <official_title>A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim is to study the effects of vorinostat on cyclin E, cyclin D1 and Ki-67
      expression in aerodigestive tract tumors (lung, esophagus, and head and neck). Secondary aims
      are: To evaluate the concentration of vorinostat in tumor tissue and to correlate tumor
      tissue distribution with the plasma level in these patients; to perform exploratory analyses
      of the effects of vorinostat on the induction of apoptosis or necrosis in treated as compared
      to untreated tumors and on expression of p21, p27, EGFR and phospho-EGFR in aerodigestive
      tract tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Tumor Markers on Tumors of the Lung, Esophagus, or Head and Neck, After 7 Days of Treatment With Vorinostat</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>Immunohistochemical score, defined as: 0, no tumor cells staining positive; 1+, 0% to 50% of tumor cells staining positive; 2+, 50% to 75% of tumor cells staining positive; and 3+, 75% to 100% of tumor cells staining positive. The change in the score before and after treatment is percentage - 0-100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Vorinostat in Tumor Tissue</measure>
    <time_frame>Day 7 from Baseline</time_frame>
    <description>Concentration of vorinostat in tumor tissue will be measured after 7 days of use of Vorinostat.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Vorinostat Treatment on Induction of Apoptosis or Necrosis in Treated vs. Untreated Tumors</measure>
    <time_frame>Baseline to day 7</time_frame>
    <description>vorinostat's effects on induction of apoptosis or necrosis in treated vs untreated tumors and on p21, p27, EGFR, and phospho-EGFR expression aerodigestive tract tumors. Immunohistochemical score is defined as follows: 0, no tumor cells staining positive; 1+, 0% to 50% of tumor cells staining positive; 2+, 50% to 75% of tumor cells staining positive; and 3+, 75% to 100% of tumor cells staining positive.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Aerodigestive Tract Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Vorinostat 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vorinostat will be administered orally once daily in an open-labeled unblinded manner to all subjects enrolled in the study. Subjects will received 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.</description>
    <arm_group_label>Vorinostat 400 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must have pathological confirmation of non small cell carcinoma of the
             aerodigestive tract (lung, esophagus, head and neck cancer).

          -  Patients must have resectable clinical stage I - III non small cell lung, clinical
             stage I-III esophageal cancer, or stage I-IV A head and neck cancer.

          -  Age &gt;18 years.

          -  Adequate hepatic and renal function documented prior to study entry to include:
             hepatic transaminases (AST or ALT) ≤ 2.0 times the upper limits of normal, total
             bilirubin ≤ 1.5 times the upper limits of normal, serum creatinine ≤ 1.5 times the
             upper limit of normal or estimated creatinine clearance ≥ 60 mL/min.

          -  All patients must be medical candidates for surgical resection of their non-small cell
             lung cancer.

          -  All patients must give informed consent indicating they are aware of the
             investigational nature of this treatment.

        Exclusion Criteria:

          -  Patients may not have received radiation therapy for their aerodigestive tract cancer.

          -  Patients may not have received chemotherapy for their aerodigestive tract cancer.

          -  Women must be surgically sterilized or post-menopausal or women of childbearing
             potential must be using an adequate method of contraception. Women of childbearing
             potential must be using at least one of the following: oral, implanted, injectable
             contraceptive hormones, or mechanical products such as an intrauterine device or
             barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing
             abstinence or have a partner that is sterile (e.g., vasectomy). Women of childbearing
             potential must have a negative serum or urine pregnancy test within 72 hours prior to
             start of study therapy.

          -  Women who are pregnant or breast-feeding will be excluded.

          -  Male patients with partners of childbearing potential not using an adequate method of
             birth control as described in the previous paragraph will be excluded.

          -  Patients with gastrointestinal abnormalities including: inability to take oral
             medication, requirement for intravenous alimentation, or prior surgical procedures
             affecting absorption will be excluded.

          -  A serious uncontrolled medical disorder or active infection which would impair their
             ability to receive study treatment will be excluded. Significant cardiac disease,
             including uncontrolled high blood pressure, unstable angina, congestive heart failure,
             myocardial infarction within the previous 3 months or serious cardiac arrythmias will
             be excluded. Dementia or significantly altered mental status that would prohibit the
             understanding or rendering of informed consent and compliance with the requirements of
             this protocol will be excluded.

          -  Patients with active HIV, Hepatitis C virus (HCV) or Hepatitis B virus (HBV)
             infection.

          -  No prior treatment with histone deacetylase (HDAC) inhibitors. Valproic acid is
             acceptable if not used as anticancer therapy and a 30-day wash-out period is allowed.

          -  Exposure to other investigational agents within 30 days of study inclusion

          -  Patients with a &quot;currently active&quot; second malignancy, other than nonmelanoma skin
             cancer and carcinoma in situ of the cervix, should not be enrolled. Patients would not
             be considered to have a &quot;currently active&quot; malignancy if they have completed therapy
             for a prior malignancy, are disease free from prior malignancies for &gt;5 years or are
             considered by their physician to be at less than 30% risk of relapse.

          -  Patients with history of pulmonary embolism who are not receiving anticoagulation,
             will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantin H. Dragnev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <results_first_submitted>July 9, 2012</results_first_submitted>
  <results_first_submitted_qc>October 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2018</results_first_posted>
  <last_update_submitted>October 8, 2018</last_update_submitted>
  <last_update_submitted_qc>October 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Konstantin Dragnev</investigator_full_name>
    <investigator_title>Staff Physician, Hematology-Oncology</investigator_title>
  </responsible_party>
  <keyword>resectable</keyword>
  <keyword>stage I-III</keyword>
  <keyword>NSCLC</keyword>
  <keyword>vorinostat</keyword>
  <keyword>esophagus</keyword>
  <keyword>head and neck</keyword>
  <keyword>proof of principle</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with clinical Stage I, II, III A NSCLC or Stage I, II , III esophageal cancer or Stage I, II, III, IV A Head and Neck cancer and a pre-treatment biopsy having at least 3 unstained slides were eligible. Patients were recruited from the oncology clinic.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vorinostat</title>
          <description>Vorinostat 400mg one daily administered orally for 7 to 10 days prior to a second biopsy/ thoracotomy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vorinostat</title>
          <description>Vorinostat group</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="17.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Tumor Markers on Tumors of the Lung, Esophagus, or Head and Neck, After 7 Days of Treatment With Vorinostat</title>
        <description>Immunohistochemical score, defined as: 0, no tumor cells staining positive; 1+, 0% to 50% of tumor cells staining positive; 2+, 50% to 75% of tumor cells staining positive; and 3+, 75% to 100% of tumor cells staining positive. The change in the score before and after treatment is percentage - 0-100</description>
        <time_frame>Baseline to Day 7</time_frame>
        <population>Participants who had at least two days days of treatment with vorinostat.</population>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat</title>
            <description>Vorinostat 400 mg once daily orally for 7 to 10 days prior to a second biopsy/ thoracotomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Tumor Markers on Tumors of the Lung, Esophagus, or Head and Neck, After 7 Days of Treatment With Vorinostat</title>
          <description>Immunohistochemical score, defined as: 0, no tumor cells staining positive; 1+, 0% to 50% of tumor cells staining positive; 2+, 50% to 75% of tumor cells staining positive; and 3+, 75% to 100% of tumor cells staining positive. The change in the score before and after treatment is percentage - 0-100</description>
          <population>Participants who had at least two days days of treatment with vorinostat.</population>
          <units>percentage of change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Changes in Ki-67 expression by immunohistochemical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="0" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in cyclin D1 expression by immunohistochem</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="0" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes in cyclin E expression by immunohistochemi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="0" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Vorinostat in Tumor Tissue</title>
        <description>Concentration of vorinostat in tumor tissue will be measured after 7 days of use of Vorinostat.</description>
        <time_frame>Day 7 from Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat Intratumoral Concentrations</title>
            <description>Vorinostat 400mg one daily administered orally for 7 days prior to a second biopsy/ thoracotomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Vorinostat in Tumor Tissue</title>
          <description>Concentration of vorinostat in tumor tissue will be measured after 7 days of use of Vorinostat.</description>
          <units>ng/mg</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6" lower_limit="0" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects of Vorinostat Treatment on Induction of Apoptosis or Necrosis in Treated vs. Untreated Tumors</title>
        <description>vorinostat's effects on induction of apoptosis or necrosis in treated vs untreated tumors and on p21, p27, EGFR, and phospho-EGFR expression aerodigestive tract tumors. Immunohistochemical score is defined as follows: 0, no tumor cells staining positive; 1+, 0% to 50% of tumor cells staining positive; 2+, 50% to 75% of tumor cells staining positive; and 3+, 75% to 100% of tumor cells staining positive.</description>
        <time_frame>Baseline to day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Necrosis</title>
            <description>Vorinostat 400mg one daily administered orally for 7 days prior to a second biopsy/ thoracotomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Vorinostat Treatment on Induction of Apoptosis or Necrosis in Treated vs. Untreated Tumors</title>
          <description>vorinostat's effects on induction of apoptosis or necrosis in treated vs untreated tumors and on p21, p27, EGFR, and phospho-EGFR expression aerodigestive tract tumors. Immunohistochemical score is defined as follows: 0, no tumor cells staining positive; 1+, 0% to 50% of tumor cells staining positive; 2+, 50% to 75% of tumor cells staining positive; and 3+, 75% to 100% of tumor cells staining positive.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vorinostat</title>
          <description>Vorinostat group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Patients were asked to take vorinostat for at least 7 days with a maximum of 10 days. Two participants did not follow directions correctly and took the pills for 3 days and 2 days. One participant took medication at 100mg per day and not the 400 mg</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Konstnatin Dragnev, MD Professor of Medicine</name_or_title>
      <organization>Dartmouth-Hitchcock Medical Center</organization>
      <phone>603-650-6344</phone>
      <email>Konstantin.H.Dragnev@Hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

